论文部分内容阅读
目的了解2型糖尿病(T2DM)及合并代谢综合征(MS)患者血浆内脏脂肪素(VFN)水平。方法对T2DM合并MS组87例、T2DM未合并MS组73例、健康对照组30例,测定其血浆VFN水平,同时测定T2DM患者的血糖、血压、血脂、C肽水平,比较3组间血浆VFN平均水平。结果MS组、非MS组及正常对照组血浆VFN水平分别为(2.13±0.64)、(1.83±0.62)、(1.00±0.33)ng/ml,组间均有显著性差异(P<0.05,P<0.001)。结论T2DM患者血浆VFN水平明显升高,合并MS者水平更高,提示血浆VFN与T2DM及MS的发生发展可能有密切关系。
Objective To investigate the plasma visfatin (VFN) levels in type 2 diabetes mellitus (T2DM) and patients with metabolic syndrome (MS). Methods 87 cases of T2DM combined with MS, 73 cases of T2DM without MS and 30 cases of healthy control were enrolled in this study. Plasma VFN level, plasma glucose, blood lipid and C-peptide levels were also measured in patients with T2DM. Plasma VFN Average. Results The plasma levels of VFN in MS group, non-MS group and normal control group were (2.13 ± 0.64), (1.83 ± 0.62) and (1.00 ± 0.33) ng / ml, respectively <0.001). Conclusions The level of plasma VFN in patients with T2DM is significantly higher than that in patients with T2DM, suggesting that plasma VFN may be closely related to the occurrence and development of T2DM and MS.